27 min
Antisense oligonucleotides Beyond Biotech - the podcast from Labiotech
-
- Tech News
German-headquartered Isarna Therapeutics is developing a portfolio of antisense therapies targeting an emerging therapeutic field in human biology – transforming growth factor beta (TGF-B) signaling. Precise modulation of TGF-B pathways using antisense therapy may result in safer and more effective treatment options for a broad range of indications.The company’s lead compound, ISTH0036, is in clinical development in ophthalmology.On the podcast this week we chat with René Rückert, chief opera...
German-headquartered Isarna Therapeutics is developing a portfolio of antisense therapies targeting an emerging therapeutic field in human biology – transforming growth factor beta (TGF-B) signaling. Precise modulation of TGF-B pathways using antisense therapy may result in safer and more effective treatment options for a broad range of indications.The company’s lead compound, ISTH0036, is in clinical development in ophthalmology.On the podcast this week we chat with René Rückert, chief opera...
27 min